Several randomized controlled trials have shown high efficacy of the vaccine in preventing pre-invasive diseases of the cervix, such as adenocarcinoma in situ, which may evolve to infiltrating carcinoma if not treated appropriately 7, 8.
Varios ensayos controlados aleatorizados han demostrado una alta eficacia de la vacuna para prevenir enfermedades preinvasivas del cuello uterino, así como el adenocarcinoma in situ, lesiones que pueden progresar a carcinoma infiltrante si no son tratadas adecuadamente 7, 8.